Tissue inhibitor of matrix metalloproteinases 4 (TIMP4) in a population of young adults: Relations to cardiovascular risk markers and carotid artery intima-media thickness. The Cardiovascular Risk in Young Finns Study

References

• Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346–59.
   PubMed Web of Science ®Google Scholar
• Romero JR, Vasan RS, Beiser AS, Polak JF, Benjamin EJ, Wolf PA, Seshadri S. Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study. J Stroke Cerebrovasc Dis 2008;17:412–7.
   PubMedGoogle Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251–62.
   PubMed Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267–83.
   PubMed Web of Science ®Google Scholar
• Rahkonen OP, Koskivirta IM, Oksjoki SM, Jokinen E, Vuorio EI. Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA. Biochim Biophys Acta 2002;1577:45–52.
   PubMedGoogle Scholar
• Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 2002;8:S332–S338.
   PubMed Web of Science ®Google Scholar
• Koskivirta I, Rahkonen O, Mayranpaa M, Pakkanen S, Husheem M, Sainio A, Hakovirta H, Laine J, Jokinen E, Vuorio E, Kovanen P, Jarvelainen H. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 2006;126:335–42.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6.
   Google Scholar
• Dollery CM, McEwan JR, Wang M, Sang QA, Liu YE, Shi YE. TIMP-4 is regulated by vascular injury in rats. Ann N Y Acad Sci 1999;878:740–1.
   PubMedGoogle Scholar
• Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999;42:162–72.
   PubMed Web of Science ®Google Scholar
• Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia- reperfusion injury. Circulation 2003;107:2487–92.
   PubMed Web of Science ®Google Scholar
• Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen K. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci 2004;75:2483–93.
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Moses MA. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun 2006;345:523–9.
   PubMedGoogle Scholar
• Raitakari OT, Juonala M, Ronnemaa T, Keltikangas-Jarvinen L, Rasanen L, Pietikainen M, Hutri-Kahonen N, Taittonen L, Jokinen E, Marniemi J, Jula A, Telama R, Kahonen M, Lehtimaki T, Akerblom HK, Viikari JS. Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol 2008;37:1220–6.
   PubMed Web of Science ®Google Scholar
• Raiko JR, Viikari JS, Ilmanen A, Hutri-Kahonen N, Taittonen L, Jokinen E, Pietikainen M, Jula A, Loo BM, Marniemi J, Lehtimaki T, Kahonen M, Ronnemaa T, Raitakari OT, Juonala M. Follow-ups of the Cardiovascular Risk in Young Finns Study in 2001 and 2007: levels and 6-year changes in risk factors. J Intern Med 2010;267: 370–84.
   PubMed Web of Science ®Google Scholar
• Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003;290:2277–83.
   PubMed Web of Science ®Google Scholar
• Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000;46:298–306.
   PubMed Web of Science ®Google Scholar
• Hoit BD, Takeishi Y, Cox MJ, Gabel M, Kirkpatrick D, Walsh RA, Tyagi SC. Remodeling of the left atrium in pacing-induced atrial cardiomyopathy. Mol Cell Biochem 2002;238:145–50.
   PubMed Web of Science ®Google Scholar
• Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Bohm M. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 2002;34:151–63.
   PubMedGoogle Scholar
• Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003;107:618–25.
   PubMed Web of Science ®Google Scholar
• Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, Guy TS, St John-Sutton MG, Gorman JH, III, Edmunds LH, Jr., Gorman RC, Spinale FG. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003;107:2857–63.
   PubMed Web of Science ®Google Scholar
• Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez-Otin C, Murphy G, Knauper V. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000;275: 14809–16.
   PubMed Web of Science ®Google Scholar
• Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 2001;276:47402–10.
   PubMed Web of Science ®Google Scholar
• Stratmann B, Farr M, Tschesche H. Characterization of C-terminally truncated human tissue inhibitor of metalloproteinases-4 expressed in Pichia pastoris. Biol Chem 2001;382:987–91.
   PubMedGoogle Scholar
• Zhao H, Bernardo MM, Osenkowski P, Sohail A, Pei D, Nagase H, Kashiwagi M, Soloway PD, DeClerck YA, Fridman R. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem 2004;279:8592–601.
   PubMed Web of Science ®Google Scholar
• Melendez-Zajgla J, Del PL, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008;7:85.
   PubMed Web of Science ®Google Scholar
• Skjot-Arkil H, Barascuk N, Register T, Karsdal MA. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol 2010;8:542–52.
   PubMed Web of Science ®Google Scholar
• Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010;52: 410–28.
   PubMed Web of Science ®Google Scholar
• Gaubatz JW, Ballantyne CM, Wasserman BA, He M, Chambless LE, Boerwinkle E, Hoogeveen RC. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol 2010;30:1034–42.
   PubMedGoogle Scholar
• Kangavari S, Matetzky S, Shah PK, Yano J, Chyu KY, Fishbein MC, Cercek B. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther 2004;9: 291–8.
   PubMed Web of Science ®Google Scholar